Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Sapkota, Bishu ^a   Hill, Charles E ^a   Pollack, Brian P ^a,b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

BRAF; Melanoma; MHC; Vemurafenib

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; VEMURAFENIB;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOLECULAR MODEL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84885816614     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22890     Document Type: Article

References (46)

1. Pollack LA, Li J, Berkowitz Z, Weir HK, Wu XC, Ajani UA, et al. Melanoma survival in the United States, 1992 to 2005. J Am AcadDermatol2011; 65(Suppl 1):S78.e1-S78.e10; http://dx.doi.org/10.1016/j.jaad.2011.05.030.
2. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-47; http://dx.doi.org/10.1056/NEJMoa050092.
3. Bastian BC, LeBoit PE, Hamm H, Bröcker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998; 58:2170-5;
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; http://dx.doi.org/10.1056/NEJMoa1103782.
5. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, NgC, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387-90; http://dx.doi.org/10.1038/ nature10662.
6. Zito CR, Kluger HM. Immunotherapy for metastatic melanoma. J Cell Biochem 2012; 113:725-34; http://dx.doi.org/10.1002/ jcb.23402.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; http://dx.doi.org/10.1056/NEJMoa1003466.
8. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116.
9. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119-27; http://dx.doi.org/10.1056/NEJMoa1012863.
10. Lampen MH, van Hall T. Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 2011; 23:293-8; http://dx.doi.org/10.1016/j.coi.2010.12.005.
11. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; http://dx.doi.org/10.1038/nrc2355.
12. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J ClinOncol 2009; 27:6199-206; http://dx.doi.org/10.1200/JCO.2009.23.4799.
13. Blank CU, Hooijkaas AI, Haanen JB, Schumacher TN. Combination of targeted therapy and immunotherapy in melanoma. Cancer ImmunolImmunother 2011; 60:1359-71; http://dx.doi.org/10.1007/s00262-011-1079-2.
14. Kline J, Zhang L, Battaglia L, Cohen KS, Gajewski TF. Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation. J Immunol 2012; 188:2630-42; http://dx.doi.org/10.4049/jimmunol.1100845.
15. Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res 2011; 17:6118-24; http://dx.doi.org/10.1158/1078-0432.CCR-11-0482.
16. Lawson DH. Choices in adjuvant therapy of melanoma. Cancer Control 2005; 12:236-41;
17. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70:5213-9; http://dx.doi.org/10.1158/0008-5472.CAN-10-0118.
18. Donia M, Fagone P, Nicoletti F, Andersen RS, Høgdall E, Thor Straten P, et al. BRAF inhibition improves tumor recognition by the immune system. OncoImmunology 2012; 1:0-7; http://dx.doi.org/10.4161/onci.21940.
19. Kono M, Dunn IS, Durda PJ, Butera D, Rose LB, Haggerty TJ, et al. Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res 2006; 4:779-92; http://dx.doi.org/10.1158/1541-7786.MCR-06-0077.
20. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012; 72:3928-37; http://dx.doi.org/10.1158/0008-5472.CAN-11-2837.
21. White CA, Thomson SA, Cooper L, van Endert PM, Tampe R, Coupar B, et al. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cellmediated immune recognition of human melanoma cells. Int J Cancer 1998; 75:590-5; h t t p: / / d x. d o i. o r g / 1 0. 1 0 0 2 / (S I C I) 1 0 9 7-0215(19980209)75:4<590::AID-IJC16> 3.0.CO;2-D.
22. Kortylewski M, Komyod W, Kauffmann ME, Bosserhoff A, Heinrich PC, Behrmann I. Interferongamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol 2004; 122:414-22; http://dx.doi.org/10.1046/ j.0022-202X.2004.22237.x.
23. Martin BK, Chin KC, Olsen JC, Skinner CA, Dey A, Ozato K, et al. Induction of MHC class I expression by the MHC class II transactivator CIITA. Immunity 1997; 6:591-600; http://dx.doi.org/10.1016/S1074-7613(00)80347-7.
24. Beresford GW, Boss JM. CIITA coordinates multiple histone acetylation modifications at the HLADRA promoter. Nat Immunol 2001; 2:652-7; http://dx.doi.org/10.1038/89810.
25. Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res 2011; 17:4400-13; http://dx.doi.org/10.1158/1078-0432.CCR-10-3283.
26. Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, et al. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci U S A 2010; 107:13794-9; http:// dx.doi.org/10.1073/pnas.1008684107.
27. Rausch MP, Hastings KT. GILT modulates CD4+ T-cell tolerance to the melanocyte differentiation antigen tyrosinase-related protein 1. J Invest Dermatol 2012; 132:154-62; http://dx.doi.org/10.1038/jid.2011.236.
28. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008; 6:751-9; http://dx.doi.org/10.1158/1541-7786.MCR-07-2001
29. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; http://dx.doi.org/10.1056/NEJMoa1002011.
30. Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010; 16:6040-8; http://dx.doi.org/10.1158/1078-0432.CCR-10-1911.
31. Madhunapantula SV, Robertson GP. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell & Melanoma Research 2009; 22:400-19; http://dx.doi.org/10.1111/j.1755-148X.2009.00585.x.
32. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1:447-56; http://dx.doi.org/10.1016/1074-7613(94)90087-6.
33. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 2008; 60:439-47; http://dx.doi.org/10.1007/s00251-008-0303-5.
34. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferonmediated rejection genes. Int J Cancer 2012; 131:387-95; http://dx.doi.org/10.1002/ijc.26471.
35. Garrido C, Paco L, Romero I, Berruguilla E, Stefansky J, Collado A, et al. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis 2012; 33:687-93; http://dx.doi.org/10.1093/carcin/ bgr318.
36. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 2010; 127:249-56;
37. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386-94; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479.
38. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma. Clin Cancer Res 2012; 18:5329-40; http://dx.doi.org/10.1158/1078-0432.CCR-12-1632.
39. Pollack BP. EGFR inhibitors, MHC expression and immune responses: Can EGFR inhibitors be used as immune response modifiers? Oncoimmunology 2012; 1:71-4; http://dx.doi.org/10.4161/onci.1.1.18073.
40. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010; 8:67; http://dx.doi.org/10.1186/1479-5876-8-67.
41. Sigalotti L, Fratta E, Parisi G, Coral S, Maio M. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success? Br J Cancer 2011; 105:327-8; http:// dx.doi.org/10.1038/bjc.2011.239.
42. Cohen EP, Kim TS. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin Cancer Biol 1994; 5:419-28;
43. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48:1019-25;
44. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, et al. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 2006; 66:6405-11; http://dx.doi.org/10.1158/0008-5472.CAN-06-0854.
45. Pollack BP, Sapkota B, Boss JM. Ultraviolet radiation-induced transcription is associated with genespecific histone acetylation. Photochem Photobiol 2009; 85:652-62; http://dx.doi.org/10.1111/j.1751-1097.2008.00485.x.
46. Hao H, Muniz-Medina VM, Mehta H, Thomas NE, Khazak V, Der CJ, et al. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. Mol Cancer Ther 2007; 6:2220-9; http://dx.doi.org/10.1158/1535-7163.MCT-06-0728.